Adverse Events Associated with Disease-Modifying Drugs for Multiple SclerosisNeurol 102:e208006, Ng, HS.,et al, 2024
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the USNeurol 91:e1778-e1787, Krysko, K.M.,et al, 2018